KYPROLIS

Product NDC
76075-101
11-digit product format
760750101
Labeler code
76075
Product ID
76075-101_600cd22c-3a74-442e-a65d-c06d47bb892a
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
carfilzomib
Dosage form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route
INTRAVENOUS
Labeler
Onyx Pharmaceuticals, Inc.
Application
NDA202714
Marketing category
NDA
Marketing start
2012-07-20
Substance
CARFILZOMIB
Active strength
60 mg/30mL
Pharmacologic classes
Proteasome Inhibitor [EPC], Proteasome Inhibitors [MoA]
NDC exclude flag
No
Listing certified through
2026-12-31
Current FDA listing
Yes

Orange Book products#

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N202714-001KYPROLISCARFILZOMIB60MG/VIALPOWDER / INTRAVENOUSAPRLD, RS2012-07-20
N202714-002KYPROLISCARFILZOMIB30MG/VIALPOWDER / INTRAVENOUSRLD, RS2016-06-03
N202714-003KYPROLISCARFILZOMIB10MG/VIALPOWDER / INTRAVENOUSRLD, RS2018-06-07

Therapeutic equivalence codes#

Application-product, TE code table
Application-productTE code
N202714-001AP

Orange Book patents#

Application-product, Patent, Expiration table
Application-productPatentExpirationUse codeCoverage / statusSubmission date
N202714-00174170422026-07-20Drug substance, Drug product2012-08-09
N202714-0017417042*PED2027-01-20Pediatric extension
N202714-00177371122027-12-07Drug product2012-08-09
N202714-0017737112*PED2028-06-07Pediatric extension
N202714-001RE479542029-10-21U-34492022-10-18
N202714-001RE47954*PED2030-04-21Pediatric extension
N202714-00194935822033-02-27Drug product2017-03-09
N202714-0019493582*PED2033-08-27Pediatric extension
N202714-001126363402041-04-29U-45512026-06-23
N202714-00112636340*PED2041-10-29Pediatric extension
N202714-00274170422026-07-20Drug substance, Drug product2016-08-15
N202714-0027417042*PED2027-01-20Pediatric extension
N202714-00277371122027-12-07Drug product2016-08-15
N202714-0027737112*PED2028-06-07Pediatric extension
N202714-002RE479542029-10-21U-34492022-10-18
N202714-002RE47954*PED2030-04-21Pediatric extension
N202714-00294935822033-02-27Drug product2017-03-09
N202714-0029493582*PED2033-08-27Pediatric extension
N202714-002126363402041-04-29U-45512026-06-23
N202714-00212636340*PED2041-10-29Pediatric extension
N202714-00374170422026-07-20Drug substance, Drug product2018-06-20
N202714-0037417042*PED2027-01-20Pediatric extension
N202714-00377371122027-12-07Drug product2018-06-20
N202714-0037737112*PED2028-06-07Pediatric extension
N202714-003RE479542029-10-21U-34492022-10-18
N202714-003RE47954*PED2030-04-21Pediatric extension
N202714-00394935822033-02-27Drug product2018-06-20
N202714-0039493582*PED2033-08-27Pediatric extension
N202714-003126363402041-04-29U-45512026-06-23
N202714-00312636340*PED2041-10-29Pediatric extension

Orange Book exclusivity#

Application-product, Exclusivity code, Expiration table
Application-productExclusivity codeExpiration
N202714-001M-142028-05-22
N202714-001PED2028-11-22
N202714-002M-142028-05-22
N202714-002PED2028-11-22
N202714-003M-142028-05-22
N202714-003PED2028-11-22

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
KYPROLISCARFILZOMIBOnyx Pharmaceuticals, Inc.ea66eb30-e665-4693-99a1-a9d3b4bbe2d62025-06-18Warnings, Adverse reactionsExact identifier

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Cardiac Toxicities : Monitor for signs and symptoms of cardiac failure or ischemia. Withhold Kyprolis and evaluate promptly. ( 5.1 ) Acute Renal Failure : Monitor serum creatinine regularly. ( 5.2 ) Tumor Lysis Syndrome (TLS) : Administer pre-treatment hydration. (2.1 ) Monitor for TLS, including uric acid levels and treat promptly. ( 5.3 ) Pulmonary Toxicity, including Acute Respiratory Distress Syndrome, Acute Respiratory Failure, and Acute Diffuse Infiltrative Pulmonary Disease : Withhold Kyprolis and evaluate promptly. ( 5.4 ) Pulmonary Hypertension : Withhold Kyprolis and evaluate. ( 5.5 ) Dyspnea : For severe or life-threatening dyspnea, withhold Kyprolis and evaluate. ( 5.6 ) Hypertension, including Hypertensive Crisis : Monitor blood pressure regularly. If hypertension cannot be controlled, interrupt treatment with Kyprolis. ( 5.7 ) Venous Thrombosis : Thromboprophylaxis is recommended. ( 5.8 ) Infusion-related Reactions : Premedicate with dexamethasone. ( 2.1 , 5.9 ) Hemorrhage : Fatal or serious cases of hemorrhage may occur, including gastrointestinal, pulmonary, and intracranial hemorrhage. Promptly evaluate signs and symptoms of blood loss. ( 5.10 ) Thrombocytopenia : Monitor platelet counts; interrupt or reduce Kyprolis dosing as clinically indicated. ( 2.3 , 5.11 ) Hepatic Toxicity and Hepatic Failure : Monitor liver enzymes regularly. Withhold Kyprolis if suspected. ( 5.12 ) Thrombotic Microangiopathy : Monitor for signs and symptoms. Discontinue Kyprolis if suspected. ( 5.13 ) Posterior Reversible Encephalopathy Syndrome (PRES) : Consider neuro-radiological imaging (MRI) for onset of visual or neurological symptoms; discontinue Kyprolis if suspected. ( 5.14 ) Progressive Multifocal Leukoencephalopathy : Consider PML if new or worsening neurologic manifestations. Discontinue Kyprolis in patients who develop PML. ( 5.15 ) Increased Fatal and Serious Toxicities in Combination with Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Patients ( 5.16 ) Embryo-Fetal Toxicity : Kyprolis can cause fetal harm. Advise females of reproductive potential and males with female partners of reproductive potential of potential risk to a fetus and to use effective contraception. ( 5.17 , 8.1 ) 5.1 Cardiac Toxicities New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edem...

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Cardiac Toxicities [see Warnings and Precautions (5.1) ] Acute Renal Failure [see Warnings and Precautions (5.2) ] Tumor Lysis Syndrome [see Warnings and Precautions (5.3) ] Pulmonary Toxicity [see Warnings and Precautions (5.4) ] Pulmonary Hypertension [see Warnings and Precautions (5.5) ] Dyspnea [see Warnings and Precautions (5.6) ] Hypertension [see Warnings and Precautions (5.7) ] Venous Thrombosis [see Warnings and Precautions (5.8) ] Infusion-Related Reactions [see Warnings and Precautions (5.9) ] Hemorrhage [see Warnings and Precautions (5.10) ] Thrombocytopenia [see Warnings and Precautions (5.11) ] Hepatic Toxicity and Hepatic Failure [see Warnings and Precautions (5.12) ] Thrombotic Microangiopathy [see Warnings and Precautions (5.13) ] Posterior Reversible Encephalopathy Syndrome [see Warnings and Precautions (5.14) ] Progressive Multifocal Leukoencephalopathy [see Warnings and Precautions (5.15) ] The most common adverse reactions occurring in at least 20% of patients treated with Kyprolis in monotherapy trials: anemia, fatigue, thrombocytopenia, nausea, pyrexia, dyspnea, diarrhea, headache, cough, edema peripheral. ( 6 ) The most common adverse reactions occurring in at least 20% of patients treated with Kyprolis in the combination therapy trials: anemia, diarrhea, hypertension, fatigue, upper respiratory tract infection, thrombocytopenia, pyrexia, cough, dyspnea, and insomnia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Amgen Medical Information at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. The pooled safety population described in the Warnings and Precautions reflect exposure to Kyprolis in 2,239 patients administered in combination with other drugs in ASPIRE, ENDEAVOR, A.R.R.O.W., CANDOR, IKEMA, EQUULEUS, and PLEIADES. The most common adverse reactions occurring in at least 20% of patients who received Kyprolis in combination were anemia, diarrhea, hypertension, fatigue, upper respirato...

adverse reactions table

Table 8: Adverse Reactions (≥ 10%) Occurring in Cycles 1–12 in Patients Who Received KRd (20/27 mg/m2 Regimen) in ASPIREAdverse ReactionsKRd (N = 392) n (%)Rd (N = 389) n (%)Any Grade≥ Grade 3Any Grade≥ Grade 3KRd = Kyprolis, lenalidomide, and dexamethasone; Rd = lenalidomide and dexamethasoneBlood and Lymphatic System Disorders Anemia138 (35)53 (14)127 (33)47 (12) Neutropenia124 (32)104 (27)115 (30)89 (23) Thrombocytopenia100 (26)58 (15)75 (19)39 (10)Gastrointestinal Disorders Diarrhea119 (30)8 (2)106 (27)12 (3) Constipation68 (17)0 (0)55 (14)1 (0) Nausea63 (16)1 (0)43 (11)3 (1)General Disorders and Administration Site Conditions Fatigue113 (29)23 (6)107 (28)20 (5) Pyrexia93 (24)5 (1)64 (17)1 (0) Edema peripheral59 (15)3 (1)48 (12)2 (1) Asthenia54 (14)11 (3)49 (13)7 (2)Infections Upper respiratory tract infection87 (22)7 (2)54 (14)4 (1) Bronchitis55 (14)5 (1)40 (10)2 (1) Viral upper respiratory tract infection55 (14)0 (0)44 (11)0 (0) PneumoniaPneumonia includes pneumonia and bronchopneumonia.54 (14)35 (9)43 (11)27 (7)Metabolism and Nutrition Disorders Hypokalemia78 (20)22 (6)35 (9)12 (3) Hypocalcemia55 (14)10 (3)39 (10)5 (1) Hyperglycemia43 (11)18 (5)33 (9)15 (4)Musculoskeletal and Connective Tissue Disorders Muscle spasms92 (24)3 (1)75 (19)3 (1) Back pain41 (11)4 (1)54 (14)6 (2)Nervous System Disorders Peripheral neuropathiesPeripheral neuropathies includes peripheral neuropathy, peripheral sensory neuropathy, and peripheral motor neuropathy.43 (11)7 (2)39 (10)4 (1)Psychiatric Disorders Insomnia64 (16)6 (2)51 (13)8 (2)Respiratory, Thoracic and Mediastinal Disorders CoughCough includes cough and productive cough.93 (24)2 (1)54 (14)0 (0) DyspneaDyspnea includes dyspnea and dyspnea exertional.71 (18)8 (2)61 (16)6 (2)Skin and Subcutaneous Tissue Disorders Rash45 (12)5 (1)54 (14)5 (1)Vascular Disorders Embolic and thrombotic eventsEmbolic and thrombotic events, venous includes deep vein thrombosis, pulmonary embolism, thrombophlebitis superficial, thrombophlebitis, venous thrombosis limb, post thrombotic syndrome, venous thrombosis.49 (13)16 (4)23 (6)9 (2) HypertensionHypertension includes hypertension, hypertensive crisis.41 (11)12 (3)15 (4)4 (1)

Additional Listing Data#

Finished product
Yes
Brand name base
KYPROLIS
Listing expiration
2026-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
CARFILZOMIB60 mg/30mL

Harmonized Identifiers#

Field, Values table
FieldValues
Unii72X6E3J5AR
Rxcui1806934, 1806937, 1806940, 1806942, 2046642, 2046644

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
db4e0bae-3add-4759-ae2c-9ede3b8f8de3Product name420200714

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
76075-101-01KYPROLIS1 in 1 CARTONINJECTION, POWDER, LYOPHILIZED,159
76075-101-01KYPROLIS30 mL in 1 VIAL, SINGLE-USEINJECTION, POWDER, LYOPHILIZED,3059
76075-101-21KYPROLIS1 in 1 CARTONINJECTION, POWDER, LYOPHILIZED,159
76075-101-21KYPROLIS30 mL in 1 VIAL, SINGLE-USEINJECTION, POWDER, LYOPHILIZED,3059

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
76075-101-01EA - Each76075-1014de4328f-ea54-4d2d-9ce5-3f207fb88af412013-02-13
76075-101-21EA - Each76075-1016483cbc6-2a0e-4087-9c36-bca56595b78e12026-03-17

DailyMed Socrata Ingredients#

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
76075-101KYPROLIS (CARFILZOMIB) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ONYX PHARMACEUTICALS, INC.]55Current NDC, Legacy NDC, 4 package rows20240926_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.zip

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
2046642carfilzomib 10 MG InjectionPSNea66eb30-e665-4693-99a1-a9d3b4bbe2d659
1806934carfilzomib 30 MG InjectionPSNea66eb30-e665-4693-99a1-a9d3b4bbe2d659
1806940carfilzomib 60 MG InjectionPSNea66eb30-e665-4693-99a1-a9d3b4bbe2d659
2046644Kyprolis 10 MG InjectionPSNea66eb30-e665-4693-99a1-a9d3b4bbe2d659
1806937Kyprolis 30 MG InjectionPSNea66eb30-e665-4693-99a1-a9d3b4bbe2d659
1806942Kyprolis 60 MG InjectionPSNea66eb30-e665-4693-99a1-a9d3b4bbe2d659
2046644carfilzomib 10 MG Injection [Kyprolis]SBDea66eb30-e665-4693-99a1-a9d3b4bbe2d659
1806937carfilzomib 30 MG Injection [Kyprolis]SBDea66eb30-e665-4693-99a1-a9d3b4bbe2d659
1806942carfilzomib 60 MG Injection [Kyprolis]SBDea66eb30-e665-4693-99a1-a9d3b4bbe2d659
2046642carfilzomib 10 MG InjectionSCDea66eb30-e665-4693-99a1-a9d3b4bbe2d659
1806934carfilzomib 30 MG InjectionSCDea66eb30-e665-4693-99a1-a9d3b4bbe2d659
1806940carfilzomib 60 MG InjectionSCDea66eb30-e665-4693-99a1-a9d3b4bbe2d659
2046644Kyprolis 10 MG InjectionSYea66eb30-e665-4693-99a1-a9d3b4bbe2d659
1806937Kyprolis 30 MG InjectionSYea66eb30-e665-4693-99a1-a9d3b4bbe2d659
1806942Kyprolis 60 MG InjectionSYea66eb30-e665-4693-99a1-a9d3b4bbe2d659

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionMarketing startMarketing endSampleExclude flagStatus
76075-101-01760750101011 VIAL, SINGLE-USE in 1 CARTON (76075-101-01) / 30 mL in 1 VIAL, SINGLE-USE2012-07-200000-00-00NoNoCurrent
76075-101-21760750101211 VIAL, SINGLE-USE in 1 CARTON (76075-101-21) / 30 mL in 1 VIAL, SINGLE-USE2025-10-01NoNoCurrent